During this briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell provide an overview of the FY25 results and a general business update.
Company News
Lumos FY25 Results Investor Briefing
03 Sep 2025
Keep reading
More news & media.
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
2 min read
100+ Locations and Growing: A Milestone for FebriDx® Adoption
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
1 min read
Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
LD
Lumos Diagnostics Communications
Written with AI assistance